Facebook
X
LinkedIn
ForwardFollowing a Moving Target: Advances in PSMA Radioligand Therapy for Prostate Cancer
The landscape of metastatic castration-resistant prostate cancer (mCRPC) continues to rapidly evolve. One of the more transformative developments in this area has been the emergence of PSMA-directed radioligand therapy (RLT), built on the foundation of highly sensitive PSMA PET imaging. These advances offer new opportunities for more precise disease assessment and targeted treatment but also introduce important questions regarding their practical integration.
To this end, this activity is designed to support clinicians in applying contemporary data on PSMA PET and RLT to the care of their patients with mCRPC. Real patient cases anchor a discussion among community- and academic-based oncologists focused on patient selection, therapeutic sequencing, toxicity monitoring/management, and multidisciplinary coordination. Each case presentation is supported by published evidence and faculty experience to demonstrate how emerging science can be translated into clinical practice.
Target Audience
This activity is designed for medical and urologic oncologists, urologists, oncology and urology nurse practitioners (NPs) and physician associates (PAs), oncology pharmacists, nuclear medicine specialists, and radiation oncologists.
Learning Objectives
- Analyze the role of PSMA-PET as a prognostic tool in PC to improve treatment selection and sequencing for patients with advanced disease
- Evaluate the application and clinical efficacy of PSMA-targeted RLTs in chemotherapy-exposed and chemotherapy-naïve mCRPC to improve identification of patients that may benefit from this modality
- Apply multidisciplinary strategies for recognizing and managing toxicities associated with PSMA-targeted RLTs to improve patient experience and long-term outcomes
Rana R. McKay, MD, FASCO (Chair)
Professor of Medicine and Urology
University of California San Diego
San Diego, CA
Neeraj Agarwal, MD, FASCO
Professor of Medicine
Senior Director for Clinical Research
Director | Center of Investigational Therapeutics
Director | Genitourinary Oncology Program
HCI, University of Utah
Salt Lake City, UT
Atif M. Hussein, MD, MMM, FACP
Program Director | Hematology Oncology Fellowship Program
Memorial Healthcare System
Clinical Associate Professor
FIU School of Medicine
University of Miami
Hollywood, FL
Priya Rudolph, MD, PhD
Clinical Associate Professor of Internal Medicine
Augusta University
Georgia Cancer Specialists, Northside Hospital Cancer Institute
Athens, GA
This activity is jointly provided by CME Outfitters, LLC, and Efficient, LLC.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by CME Outfitters, LLC, and Efficient, LLC. CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation Statement
Physician Continuing Education (ACCME)
CME Outfitters, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development (ANCC)
This activity is designated 0.75 contact hours.
Physician Associates (AAPA)
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until the program expiration date. PAs should only claim credit commensurate with the extent of their participation.
Pharmacy Continuing Education (ACPE)
This application-based activity is approved for 0.75 contact hours (0.075 CEUs) of continuing pharmacy credit (JA0007185-9999-25-120-H01-P).
Other Healthcare Professionals
A Certificate of Participation will be given upon completion of the enduring activity enabling participants to register their credit with the appropriate licensing boards or associations.
Disclosure of Relevant Financial Relationships
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Faculty Disclosures
Advisory Board and Consultant: Ambrx; Arcus Biosciences, Inc.; AstraZeneca; AVEO Pharmaceuticals, Inc.; Bayer; Blue Earth Diagnostics; Bristol Myers Squibb (BMS); Calithera Biosciences, Inc.; Caris Life Sciences; Daiichi Sankyo, Inc.; Dendreon Pharmaceuticals LLC; Exelixis; Johnson & Johnson ; Lilly; Merck & Co., Inc.; Myovant Sciences; Neomorph; Nimbus Therapeutics; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sanofi; Seagen Inc.; Sorrento Therapeutics, Inc.; Telix Pharmaceuticals; and Tempus
Research Support: Institutional research funding from Artera AI; AstraZeneca; Bayer; BMS; Exelixis; Oncternal Therapeutics; and Tempus
Dr Agarwal discloses the following:
Research Support: Research funding to Neeraj Agarwal’s institution: Arnivas; Astellas Pharma Inc.; AstraZeneca; Bavarian Nordic; Bayer; BMS; Calithera Biosciences, Inc.; Celldex Therapeutics; Clovis Oncology; CRISPR Therapeutics; Eisai Inc.; EMD Serono; Exelixis, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GSK; Immunomedics, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics N.V.; Lilly; Medivation, Inc.; Merck & Co., Inc.; Nektar Therapeutics; Neoleukin Therapeutics; NewLink Genetics; Novartis Pharmaceuticals Corporation; ORIC Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus Laboratories; Rexahn Pharmaceuticals; Roche; Sanofi; Seattle Genetics, Inc.; Takeda Pharmaceutical Company Limited; and TRACON Pharmaceuticals, Inc.
Dr Rudolph discloses the following:
Advisory Board: Daiichi Sankyo, Inc.; Lilly; and Pfizer Inc.
Speaker's Bureau: AstraZeneca; Daiichi Sankyo, Inc.; Gilead Sciences, Inc.; Lilly; Puma Biotechnology, Inc.; Pfizer Inc.; and Stemline Therapeutics, Inc.
Dr Hussein reports no financial relationships to disclose.
Accredited Provider Disclosure
CME Outfitters, LLC staff have no disclosures to report.
Planners and managers have no disclosures to report:
Thomas Mitchell, MSW, LSW
Taylor Wallace, PhD (Planning Committee)
Chloe Billings, MS (Planning Committee)
Brian Moss (Planning Committee)
Sharon Tordoff (Planning Committee)
Instructions to Claim Credit
In order to receive CME/CE credits, participants must complete the pre-assessment questions, post-assessment, and program evaluation. Certificates will be distributed online at the conclusion of the activity.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, Efficient, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Commercial Support
This activity is supported by an independent educational grant from Novartis.
Available Credit
- 0.75 AAPA Category I CME
- 0.75 ACPE Pharmacy
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Attendance